Clinical Trial Update: Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating surufatinib combined with toripalimab in recurrent or metastatic nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: UNKNOWN